PSA targeted dual-modality manganese oxide–mesoporous silica nanoparticles for prostate cancer imaging
PSA targeted dual-modality manganese oxide–mesoporous silica nanoparticles for prostate cancer imaging is a paper indexed in ScholarIQ from OpenAlex.
How many citations does PSA targeted dual-modality manganese oxide–mesoporous silica nanoparticles for prostate cancer imaging have?
PSA targeted dual-modality manganese oxide–mesoporous silica nanoparticles for prostate cancer imaging has 60 citations in the OpenAlex counts ScholarIQ stores.
When was PSA targeted dual-modality manganese oxide–mesoporous silica nanoparticles for prostate cancer imaging published?
PSA targeted dual-modality manganese oxide–mesoporous silica nanoparticles for prostate cancer imaging has 2019 year in the ScholarIQ index.
What is the open-access status of PSA targeted dual-modality manganese oxide–mesoporous silica nanoparticles for prostate cancer imaging?
PSA targeted dual-modality manganese oxide–mesoporous silica nanoparticles for prostate cancer imaging has gold oa status in the ScholarIQ index.
What is the DOI of PSA targeted dual-modality manganese oxide–mesoporous silica nanoparticles for prostate cancer imaging?
The DOI for PSA targeted dual-modality manganese oxide–mesoporous silica nanoparticles for prostate cancer imaging is on the source record.
What is the PMID of PSA targeted dual-modality manganese oxide–mesoporous silica nanoparticles for prostate cancer imaging?
The PMID for PSA targeted dual-modality manganese oxide–mesoporous silica nanoparticles for prostate cancer imaging is on the source record.
What is the OpenAlex record for PSA targeted dual-modality manganese oxide–mesoporous silica nanoparticles for prostate cancer imaging?
The OpenAlex for PSA targeted dual-modality manganese oxide–mesoporous silica nanoparticles for prostate cancer imaging is on the source record.